Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America. Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
How does Pentax Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pentax Medical's score of 13 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Pentax Medical reported total carbon emissions of approximately 866,000 kg CO2e, a slight decrease from about 886,000 kg CO2e in 2022. The emissions breakdown reveals that Scope 1 emissions accounted for about 52,000 kg CO2e, while Scope 2 emissions were approximately 29,000 kg CO2e. The majority of their emissions, about 785,000 kg CO2e, fell under Scope 3, indicating significant indirect emissions associated with their value chain. Despite the reduction in total emissions, Pentax Medical has not disclosed specific reduction targets or initiatives aimed at further decreasing their carbon footprint. The absence of formal climate pledges or Science-Based Targets Initiative (SBTi) commitments suggests that while the company is monitoring its emissions, it may not yet have established a comprehensive strategy for long-term climate action.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | |
---|---|---|
Scope 1 | 52,000 | 00,000 |
Scope 2 | 29,000 | 00,000 |
Scope 3 | 804,000 | 000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pentax Medical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.